Abstract: INFO11-SA
Clinical Phenotyping Resource and Biobank Core (CPROBE): A Longitudinal Observational Cohort of Kidney Diseases
Session Information
- Informational Posters - 3
October 26, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- No subcategory defined
Authors
- Bitzer, Markus, University of Michigan, Ann Arbor, Michigan, United States
- Gadegbeku, Crystal A., Cleveland Clinic, Cleveland, Ohio, United States
- Troost, Jonathan P., University of Michigan, Ann Arbor, Michigan, United States
- Lienczewski, Chrysta C., University of Michigan, Ann Arbor, Michigan, United States
- Ju, Wenjun, University of Michigan, Ann Arbor, Michigan, United States
- Pennathur, Subramaniam, University of Michigan, Ann Arbor, Michigan, United States
- Kretzler, Matthias, University of Michigan, Ann Arbor, Michigan, United States
Description
The Clinical Phenotyping Resource and Biobank Core (C-PROBE) is a longitudinal observational cohort study that has enrolled over 1700 patients with kidney disease from Nephrology clinics at 5 sites, including 275 pediatric patients over the past 15 years. It includes a bank of biosamples (urine, blood and tissue) and data-rich clinical information.
Participants are enrolled at a baseline visit, and followed annually at regularly scheduled clinical care appointments, in which data updates are procured as well as biospecimens, including blood and urine. Current disease etiology breakdown is 37% Glomerular, 16% Diabetic Nephropathy, 18% Tubulointerstitial, 16% Hypertension, 1% CAKUT, 12% Hereditary/Other. Biological specimens include remnant kidney tissue, blood including plasma (EDTA), serum (SST), DNA and RNA, and urine preserved with both protease inhibitor and sodium azide. Demographic data collected annually includes age (at enrollment), annual household income, educational level, race and ethnicity, gender, height and weight, employment status, and primary type of work, among others. Gender breakdown is 52% female, 48% male; with race representation of 1% American Indian/Alaskan Native, 3% Asian/Asian American, 39% Black/African American, 52% Caucasian/White, 3% Multiracial and 1% Not reported. 9% Self identify as Hispanic.
Median follow-up for the full cohort is 50 months (IQR=25 to 74). 33.78% of Black participants experienced 40% or greater decline in eGFR, with 41.18% of white participants having the same decline. All-cause mortality of 11.95% Black and 9.32% white were also observed. The study has 45,600 plasma and serum samples, 53,400 urine derived samples, and remnant tissue in RNA-Later from 129 renal biopsies.
C-PROBE has established an infrastructure that serves as an interface between patients in the clinical care settings and biomedical investigators conducting translational research in kidney disease. The data and biospecimen have already contributed significantly to many research studies.
Funding
- The Renal Pre-Competitive Consortium (RPC2)